Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 3Prostatic Neoplasms 2Overweight 2Obesity 2Melanoma 2Substance Withdrawal Syndrome 1Skin Neoplasms 1Kidney Neoplasms 1Glioma 1Glioblastoma 1Chronic Pain 1Carcinoma, Lobular 1Carcinoma, Intraductal, Noninfiltrating 1Breast Carcinoma In Situ 1

Interventions

Letrozole 6Radiotherapy 4Carboplatin 4atamestane 3Trastuzumab 3Toremifene 3Magnetic Resonance Spectroscopy 3Fulvestrant 3Docetaxel 3Cyclophosphamide 3Chemotherapy, Adjuvant 3Tamoxifen 2Paclitaxel 2Estrogen Receptor Modulators 2Capecitabine 2Aromatase Inhibitors 2repotrectinib 1proto-oncogene protein c-fes-fps 1palbociclib 1neratinib 1gallium 68 PSMA-11 1fluciclovine F-18 1entrectinib 1Zolpidem 1Vorinostat 1Vinorelbine 1Venlafaxine Hydrochloride 1Thiotepa 1Taxes 1Sugars 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Carcinoma, Lobular × Naltrexone × Clear all
NCT02137252 2021-11-16

Naltrexone RCT for Treatment-Emergent Fatigue in Patients Receiving Radiation Therapy for Breast Cancer

Dana-Farber Cancer Institute

Phase 2 Terminated
3 enrolled 4 charts
Breast

Breast Carcinoma In Situ, Carcinoma, Intraductal, Noninfiltrating, Carcinoma, Lobular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡